期刊文献+

厄贝沙坦联合卡托普利治疗高血压并发微量白蛋白尿患者疗效观察 被引量:3

The clinical investigation of the combination of irbesartan and captopril on hypertensive patients with microalbuminuria
原文传递
导出
摘要 目的:观察厄贝沙坦和卡托普利联合治疗高血压并发微量白蛋白尿患者的降压效果和减少尿微量白蛋白效果。方法:采用随机分组对照法将84例原发性高血压病并发微量白蛋白尿患者分为三组:厄贝沙坦治疗组26例;卡托普利治疗组28例;厄贝沙坦联合卡托普利治疗组30例。观察4周,收集血压、尿素氮、尿微量白蛋白等指标。结果:三组均能显著降低血压和尿微量白蛋白,但联合治疗组较任一单用组更显著减少了尿微量白蛋白(P<0.05)。结论:厄贝沙坦与卡托普利联合治疗高血压并发微量蛋白尿患者不但能有效的控制高血压还具有显著的肾功能保护作用。 Objective:To study the therapeutic effects of the combination of irbesartan and captopril in 84 hy- pertensive patients with microalbuminuria. Method: In this study, 84 hypertensive patients with microalbuminuria were divided into three groups according to the anti-hypertension drugs. 26 patients were treated with irhesartan; 28 patients were treated with captopril and 30 patients were treated with irbesartan and captopril. The antihyper- tension effect and the UREP after the treatment were compared in these three groups. Result:Patients in the three groups have similar anti-hypertension effect, but the UREP of the combination group is better than the other two group, (P〈0.05). Conclusion:The combination of irbesartan and captopril is better than single use in the protec- tion renal function.
作者 孙均
出处 《临床急诊杂志》 CAS 2012年第5期330-331,334,共3页 Journal of Clinical Emergency
关键词 高血压 厄贝沙坦 卡托普利 微量白蛋白尿 hypertension irhesartan captopril microalbimin
  • 相关文献

参考文献6

  • 1CHOBANIAN A V, BAKRIS G L, BLACK H R, et al. The seventh report of the joint national committee on prevention, dewction, evaluation and treatment of high blood pressure the JNC 7 report[J]. JAMA,2003,289:2560-2572. 被引量:1
  • 2余钷,黄志培.美托洛尔和卡托普利对扩张型心肌病的干预治疗比较[J].临床急诊杂志,2010,11(4):214-215. 被引量:2
  • 3SARASUA S M,MUELLER P,KATHMAN S,et al. Confirming the utility of four kidney biomarker tests in a longitudinal follow-up study[J]. Ren Fail, 2003, 25:797-817. 被引量:1
  • 4BARRI Y M. Hypertension and kidney disease: deadly eonneetion[J]. Cur Hypertens Rep, 2008,10:39-45. 被引量:1
  • 5COMPER W D, OSICKA T M, JERUMS G, et al. High prevalence of immuno-unreactive intact albumin in the urine of diabetic patients[J]. Am J Kid, 2003, 41:336-342. 被引量:1
  • 6WENZEL U O,THAISS F,H ELM C U, et al. Angiotensin Ⅱ infusion ameliorates the early phase of a mesangioproliferative glomerulonephritis[J]. Kidney Int, 2002,61: 1020- 1029. 被引量:1

二级参考文献4

共引文献1

同被引文献29

  • 1张巧丽,王宝金.卡托普利合厄贝沙坦治疗高血压肾损害的疗效[J].求医问药:下半月,2012,2(12):173-174. 被引量:1
  • 2范序.厄贝沙坦和复方利衄平片对高血压患者颈动脉内膜中层厚度的影响[J].实用心脑肺血管病杂志,2013,21(12):136.137. 被引量:1
  • 3HALLER H, ITO S, IZZO J L, et al. Olmesartan for the de- lay or prevention of microalbuminuria in type 2 diabetes[J]. The New England Journal of Medicine, 2011,364 (10) : 907- 917. 被引量:1
  • 4SARASUA S M, MUELLER P, KATHMAN S, et al. Con firming the utility of four kidney biomarker tests in a longitu dinal follow-up study[J]. Ren Fail, 2003,25 : 797-817. 被引量:1
  • 5BARRI Y M. Hypertension and kidney disease: a deadly con neetion[J]. Current Cardiology Reports, 2006,8(6):411-417. 被引量:1
  • 6COMPER W D, OSICKA T M, JERUMS G, et al. High prevalence of immuno-unreactive intact albumin in the urine of the diabetic patients[J]. Am J Kid, 2003,41 : 336- 342. 被引量:1
  • 7MIURA S, FUJINO M, HANZAWA H, et al. Molecular mechanism-underlying inverse agonist of angiotensin II type 1 receptor[J]. J Biol Chem, 2006,281:19288-19295. 被引量:1
  • 8MIURA S, KIYA Y, KANAZAWA T, et al. Differential bonding interactions of inverse agonists of angiotensin Ⅱtype 1 receptor in stabilizing the inactive state[J]. Mol Endocrinol, 2008,22,139-146. 被引量:1
  • 9FUJITA M, OKUDA H, TSUKAMOTO O, et al. Blockade of angiotensin Ⅱ receptors reduces the expression of receptors for advanced glycation and products in human endothelial cells [J]. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006,26(10) :e138-e142. 被引量:1
  • 10LIANG H, CHEN H Z. Comparison of olmesartan medoxomil and eandesartan cilexetil on anti-inflammatory effect in athero sclerotic rats[J]. Heart, 2010,96 : A68. 被引量:1

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部